GLP-1 receptor agonists like semaglutide and tirzepatide started as diabetes drugs. Cardiovascular outcome trials and early longevity data suggest their effects extend far beyond weight loss. Here's what the science shows and what you can do without a prescription.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are dominating longevity conversations in 2026. Bryan Johnson added them to his Immortals Rx platform. Longevity physicians including Peter Attia have discussed them at length. The question is no longer whether these drugs do interesting things — they clearly do — but whether those things translate to lifespan extension in people who don't have obesity or diabetes.
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals satiety to the brain, slows gastric emptying, stimulates insulin secretion, and suppresses glucagon. Pharmaceutical GLP-1 agonists mimic and amplify this effect, binding GLP-1 receptors throughout the body — including in the heart, kidneys, liver, and brain.
The weight loss effect is real and substantial: semaglutide at 2.4 mg weekly produced 14.9% mean weight loss in the STEP 1 trial. Tirzepatide, which also agonizes GIP receptors (making it dual-acting), produced 20–22% weight loss at the highest dose in the SURMOUNT-1 trial — equivalent to bariatric surgery in some comparisons.
But the longevity interest isn't primarily about weight. It's about the downstream effects on cardiovascular disease, kidney function, metabolic inflammation, and potentially neural health.
The clearest case for GLP-1 agonists in longevity is the cardiovascular outcome trial data.